Virtu Financial LLC Invests $1.99 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Virtu Financial LLC purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 17,230 shares of the company's stock, valued at approximately $1,985,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Ashton Thomas Private Wealth LLC bought a new position in shares of Neurocrine Biosciences during the 2nd quarter valued at about $28,000. Innealta Capital LLC purchased a new position in shares of Neurocrine Biosciences during the second quarter worth approximately $30,000. EdgeRock Capital LLC purchased a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at $35,000. Blue Trust Inc. raised its position in Neurocrine Biosciences by 171.9% in the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company's stock worth $40,000 after purchasing an additional 220 shares during the period. Finally, Plato Investment Management Ltd boosted its position in Neurocrine Biosciences by 44.1% during the second quarter. Plato Investment Management Ltd now owns 425 shares of the company's stock valued at $59,000 after buying an additional 130 shares during the period. Hedge funds and other institutional investors own 92.59% of the company's stock.

Insiders Place Their Bets

In other news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the sale, the insider now directly owns 15,449 shares in the company, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

NBIX has been the subject of a number of analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Monday, September 16th. HC Wainwright reaffirmed a "buy" rating and issued a $190.00 price target on shares of Neurocrine Biosciences in a research note on Friday, November 1st. BMO Capital Markets reduced their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating on the stock in a research report on Thursday, October 17th. StockNews.com lowered shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Friday, November 1st. Finally, Barclays decreased their price target on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating for the company in a research note on Monday, September 9th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $165.18.

Neurocrine Biosciences Stock Performance

Shares of NBIX traded down $0.09 during mid-day trading on Friday, hitting $126.70. 777,757 shares of the stock were exchanged, compared to its average volume of 866,688. The company has a market cap of $12.83 billion, a PE ratio of 33.97 and a beta of 0.34. Neurocrine Biosciences, Inc. has a 52-week low of $110.95 and a 52-week high of $157.98. The firm has a 50-day moving average of $121.49 and a two-hundred day moving average of $130.78.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.